Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ilixadencel - Mendus

Next Previous
Search
Drug Profile

Ilixadencel - Mendus

Alternative Names: Allogeneic cancer vaccine - Mendus ; COMBIG-DC; Dendritic cell vaccine - Mendus ; INTUVAX-GIST; INTUVAX-HCC; INTUVAX-RCC

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunicum
  • Developer Mendus; Uppsala University
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastrointestinal stromal tumours; Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gastrointestinal stromal tumours; Liver cancer; Solid tumours
  • No development reported Gastric cancer; Head and neck cancer; Non-small cell lung cancer
  • Discontinued Renal cell carcinoma

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Gastric-cancer(Combination therapy) in Sweden (Intratumoural)
  • 28 Nov 2024 No recent reports of development identified for preclinical development in Head-and-neck-cancer(Combination therapy) in Sweden (Intratumoural)
  • 28 Nov 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer(Combination therapy) in Sweden (Intratumoural)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top